Syndax Pharmaceuticals, Inc.
SNDX
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDā¦ read more
Healthcare
Biotechnology
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$15.04
Price+2.38%
$0.35
1Y
Price
Market Cap
$1.302b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-168.6%
EBITDA Margin-189.3%
Net Profit Margin-231.3%
Free Cash Flow MarginRevenue
$78.180m
+230.2%
1y CAGR+76.7%
3y CAGR+32.5%
5y CAGREarnings
-$334.988m
-5.1%
1y CAGR-34.3%
3y CAGR-194.9%
5y CAGREPS
-$3.90
-4.6%
1y CAGR-18.5%
3y CAGR-167.7%
5y CAGRBook Value
$157.424m
$596.149m
Assets$438.725m
Liabilities$1.675m
DebtDebt to Assets
0.3%
-
Debt to EBITDAFree Cash Flow
-$302.667m
-10.1%
1y CAGR-33.7%
3y CAGR-165.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company